Myeloproliferative neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Myeloproliferative neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Gandotinib for Patients with Myeloproliferative Neoplasms, Myelofibrosis, Essential Thrombocythemia, or Polycythemia Vera https://clinicaltrials.eu/trial/study-of-gandotinib-for-patients-with-myeloproliferative-neoplasms-myelofibrosis-essential-thrombocythemia-or-polycythemia-vera/ Thu, 11 Jun 2026 04:06:33 +0000 https://clinicaltrials.eu/trial/study-of-gandotinib-for-patients-with-myeloproliferative-neoplasms-myelofibrosis-essential-thrombocythemia-or-polycythemia-vera/ This clinical trial is focused on studying a group of blood cancers known as myeloproliferative neoplasms (MPNs). These include specific conditions such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The treatment being tested in this study is a medication called gandotinib, which is also known by its code name LY2784544. The purpose of the study is to evaluate how effective this medication is in treating these blood cancers.

Participants in the study will take the medication in the form of a capsule, which is taken by mouth once a day. The study will monitor the response to the treatment over a period of time to see how well it works in managing the conditions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to gather information on how the medication affects the body and its potential side effects.

By participating in this study, researchers hope to better understand the effectiveness of gandotinib in treating myeloproliferative neoplasms and to explore its potential as a treatment option for patients with these conditions. The study will help determine if this medication can improve the quality of life for those affected by these blood cancers.

]]> Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms https://clinicaltrials.eu/trial/study-on-apixaban-rivaroxaban-and-aspirin-for-preventing-blood-clots-in-patients-with-jak2v617f-positive-myeloproliferative-neoplasms/ Wed, 29 Apr 2026 15:01:08 +0000 https://clinicaltrials.eu/trial/study-on-apixaban-rivaroxaban-and-aspirin-for-preventing-blood-clots-in-patients-with-jak2v617f-positive-myeloproliferative-neoplasms/ This clinical trial is focused on studying a group of blood disorders known as Philadelphia-negative myeloproliferative neoplasms. These disorders include Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. These conditions are chronic and involve the overproduction of blood cells. The study aims to compare the effectiveness of two types of medications in preventing blood clots in patients with these disorders who have a specific genetic mutation called JAK2V617F. The medications being tested are Apixaban and Rivaroxaban, which are known as direct oral anticoagulants (DOACs), and they will be compared to Aspirin, a commonly used medication for preventing blood clots.

The purpose of the study is to determine if low-dose DOACs are more effective than low-dose Aspirin in preventing blood clots in high-risk patients with these blood disorders. Participants in the study will be randomly assigned to receive either Apixaban, Rivaroxaban, or Aspirin. The study will monitor the time it takes for any blood clotting events to occur, as well as any significant bleeding events. The study will also look at other health outcomes, such as overall survival and quality of life, over a period of 24 months.

Throughout the study, participants will take their assigned medication orally, and their health will be closely monitored by the research team. The study will help to better understand which medication is more effective in preventing complications related to blood clots in patients with these specific blood disorders. The findings could lead to improved treatment options for individuals with these conditions.

]]> Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia https://clinicaltrials.eu/trial/study-on-long-term-safety-of-pelabresib-for-patients-with-myelofibrosis-or-essential-thrombocythemia/ Wed, 29 Apr 2026 15:00:03 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-pelabresib-for-patients-with-myelofibrosis-or-essential-thrombocythemia/ This clinical trial is focused on studying the long-term effects of a treatment called pelabresib in patients with certain blood disorders known as myeloproliferative neoplasms, specifically myelofibrosis and essential thrombocythemia. These conditions involve the abnormal growth of blood cells in the bone marrow, which can lead to various health issues. The treatment being studied, pelabresib, is a type of medication known as a small molecule bromodomain inhibitor, which works by targeting specific proteins involved in the growth of these abnormal cells.

The purpose of this study is to evaluate the long-term safety and potential benefits of pelabresib for patients who have already been receiving this treatment in previous studies. Participants will continue to take pelabresib in the form of a tablet, and their health will be monitored over time to assess any side effects and overall survival. The study will also look at how long patients continue to benefit from the treatment and how it affects their quality of life.

Throughout the study, patients will have regular check-ups to monitor their condition and any changes in their health. The study aims to provide valuable information about the safety and effectiveness of pelabresib for managing myeloproliferative neoplasms, helping to improve treatment options for these conditions in the future.

]]> Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-navitoclax-and-ruxolitinib-for-patients-with-myelofibrosis-and-myeloproliferative-neoplasms/ Wed, 29 Apr 2026 14:28:58 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-navitoclax-and-ruxolitinib-for-patients-with-myelofibrosis-and-myeloproliferative-neoplasms/ This clinical trial is focused on studying the safety and effects of a medication called Navitoclax, both on its own and in combination with another medication called Ruxolitinib. The study is aimed at individuals with a group of diseases known as Myeloproliferative Neoplasms, which include conditions like Myelofibrosis. These diseases involve the abnormal growth of blood cells in the bone marrow. The trial also examines how Navitoclax affects the body when taken with Celecoxib, a medication often used for pain and inflammation.

The purpose of the study is to evaluate the safety, tolerability, and how the body processes these medications. Participants will receive the medications in different combinations and doses, and their health will be monitored closely. The study will also look at how Navitoclax affects the heart’s electrical activity, which is measured by a test called an ECG (electrocardiogram). This is important to ensure that the medications do not cause any harmful effects on the heart.

Throughout the study, participants will undergo regular health checks, including physical exams and laboratory tests, to monitor their response to the treatment. The study aims to gather information on the potential benefits and any side effects of the medications, helping to improve treatment options for people with Myeloproliferative Neoplasms.

]]> Study on the Effects of Atorvastatin for Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms https://clinicaltrials.eu/trial/study-on-the-effects-of-atorvastatin-for-patients-with-philadelphia-negative-chronic-myeloproliferative-neoplasms/ Wed, 29 Apr 2026 14:22:34 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-atorvastatin-for-patients-with-philadelphia-negative-chronic-myeloproliferative-neoplasms/ This clinical trial is focused on studying certain types of blood cancer known as Philadelphia-negative chronic myeloproliferative neoplasms. These include essential thrombocythemia, polycythemia vera, and prefibrotic myelofibrosis. The treatment being tested in this study is a medication called atorvastatin, which is commonly used to lower cholesterol levels. In this trial, atorvastatin is being used to see if it can help reduce inflammation and improve blood cell counts in patients who are already receiving the best available therapy for their condition.

The purpose of the study is to investigate the effects of adding atorvastatin to the current treatment regimen for these blood cancers. Participants in the study will take atorvastatin in the form of film-coated tablets, which are taken orally. The study will compare the results of those taking atorvastatin with those who are not, to see if there are any differences in inflammation markers and blood cell counts. The study will last for a period of up to 24 months, during which time participants will be monitored regularly.

Throughout the study, researchers will focus on measuring certain indicators of inflammation, such as hs-CRP and inflammatory cytokines, as well as blood cell counts, including leukocyte and platelet counts. The study aims to provide more information on whether atorvastatin can be a beneficial addition to the treatment of these specific types of blood cancer. Participants will be closely monitored to ensure their safety and to gather data on the effectiveness of the treatment.

]]>